Endometrial Cancer Clinical Trials in Portland, Oregon

19 studies are recruiting for endometrial cancer in Portland, Oregon right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Oregon Health & Science University (OHSU), Portland, Oregon
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  2. Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

    This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / N…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Providence Portland Medical Centre, Portland, Oregon
    Locations
    121 in total
    Run by
    Canadian Cancer Trials Group

    See if you can join NCT05640999 on ClinicalTrials.gov

  3. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Portland Medical Center, Portland, Oregon
    Locations
    26 in total
    Run by
    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

  4. Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

    The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …

    Stage
    Phase 3
    Ages
    18 and older
    Site
    USOR - NW Cancer Specs P.C., Portland, Oregon
    Locations
    171 in total
    Run by
    Genmab

    See if you can join NCT07166094 on ClinicalTrials.gov

  5. A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

    This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive soli…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Cancer Institute of Oregon, Portland, Oregon
    Locations
    15 in total
    Run by
    Context Therapeutics Inc.

    See if you can join NCT06515613 on ClinicalTrials.gov

  6. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Research Site, Portland, Oregon
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

  7. Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

    This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors

    Stage
    Phase 1
    Ages
    18 to 130
    Site
    Research Site, Portland, Oregon
    Locations
    60 in total
    Run by
    AstraZeneca

    See if you can join NCT05797168 on ClinicalTrials.gov

  8. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage
    Phase 2
    Ages
    18 to 130
    Site
    Research Site, Portland, Oregon
    Locations
    96 in total
    Run by
    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

  9. A Study of MGC026 in Participants With Advanced Solid Tumors

    The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort ex…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Cancer Institute, Portland, Oregon
    Locations
    12 in total
    Run by
    MacroGenics

    See if you can join NCT06242470 on ClinicalTrials.gov

  10. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Compass Oncology - Rose Quarter, Portland, Oregon
    Locations
    66 in total
    Run by
    Genmab

    See if you can join NCT05579366 on ClinicalTrials.gov

  11. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Oregon Health & Science University, Portland, Oregon
    Locations
    82 in total
    Run by
    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

  12. Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

    This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following pla…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Portland, Oregon
    Locations
    320 in total
    Run by
    AstraZeneca

    See if you can join NCT07044336 on ClinicalTrials.gov

  13. Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors

    This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341 administered orally as a single agent or combination therapy in patients w…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Investigative Site #121, Portland, Oregon
    Locations
    15 in total
    Run by
    MOMA Therapeutics

    See if you can join NCT06974110 on ClinicalTrials.gov

  14. A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

    This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Portland Cancer Institute, Portland, Oregon
    Locations
    21 in total
    Run by
    Alliance Foundation Trials, LLC.

    See if you can join NCT04486352 on ClinicalTrials.gov

  15. cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

    This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, bladder, cervical, colorectal, endometrial, esophageal, gast…

    Stage
    Not phased
    Ages
    40 and older
    Site
    Oregon Health Sciences University, Portland, Oregon
    Locations
    17 in total
    Run by
    Adela, Inc

    See if you can join NCT05366881 on ClinicalTrials.gov

  16. Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

    This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Northwest Cancer Specialists, P.C., Portland, Oregon
    Locations
    18 in total
    Run by
    Faeth Therapeutics

    See if you can join NCT06463028 on ClinicalTrials.gov

  17. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Providence Cancer Institute, Portland, Oregon
    Locations
    13 in total
    Run by
    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

  18. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Portland, Oregon
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  19. Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

    This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses …

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Northwest Cancer Specialists, Portland, Oregon
    Locations
    83 in total
    Run by
    Kartos Therapeutics, Inc.

    See if you can join NCT05797831 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.